CLL | Tumor

CURE’s Chronic Lymphocytic Leukemia (CLL) page features the latest cancer news and updates on CLL Through articles, videos, podcasts, and more, CURE brings readers the insights of experts, cancer survivors, patients, and advocates to ensure everyone is up to date in chronic lymphocytic leukemia.

CAR-T Cell Therapy May Confer Responses in Relapsed/Refractory CLL or SLL, Preliminary Data Shows

February 1st 2023

The TRANSCNED CLL 004 trial met its primary endpoint of complete responses with the CAR-T cell therapy Breyanzi in patients with relapsed or refractory CLL or SLL.

Brukinsa Offers Better Response and Less Toxicity for CLL and SLL Treatment, But a Cure Is Still Needed

January 30th 2023

Two experts explain what patients need to know about the recent approval of Brukinsa for patients with chronic lymphocytic leukemia and small lymphocytic leukemia.

FDA Approves Brukinsa for Two Leukemia Types

January 19th 2023

The Food and Drug Administration approved Brukinsa for patients with chronic lymphocytic leukemia or small lymphocytic leukemia.

At the Start of 2023, I’m Reflecting on My New Normal With Cancer

January 11th 2023

Life looks a bit different after my cancer diagnosis and the COVID-19 pandemic, making me even more grateful for the people in my life.

Living Life Between Cancer Appointments

December 26th 2022

When cancer entered our life, fear was a constant. However, we tried to live as joyously as possible between check-ups.

Survival and Treatment Response May Be Further Improved With Brukinsa Versus Imbruvica for CLL/SLL

December 14th 2022

Progression-free survival and overall response rates greatly improved in patients with CLL/SLL treated with Brukinsa compared with Imbruvica.

Calquence Tends to Be a Shorter-Lived Frontline Regimen Than Imbruvica for Leukemia Subtype

December 13th 2022

Patients with chronic lymphocytic leukemia tended to switch to another regimen or intensify their Calquence treatment quicker than those given Imbruvica, study results showed.

Switching to Subcutaneous Medication for My Cancer-Induced Compromised Immune System Was Life Changing

December 9th 2022

Once I got the hang of administering subcutaneous immunoglobulin, my life was so much easier, as I no longer had to undergo monthly IV infusions for my cancer-related compromised immune system.

When It Comes to Cancer, Are We What We Eat?

November 16th 2022

After being diagnosed with cancer 13 years ago, I began to wonder if my diet had anything to do with it — so I made some changes to eat better.

Can Baking Bread Be Cancer Therapy?

November 1st 2022

I made a point to continue baking a weekly challah bread after I was diagnosed with blood cancer, and it proved to be therapeutic.

My Oncologist Gave Me Hope

October 22nd 2022

After being diagnosed with lymphoma, I scheduled consultations with three oncologists, but only one provided me with the hope I needed.

First Patient Receives Investigational CAR-T Cell Therapy in Trial Assessing the Treatment for Lymphoma, Leukemia

October 14th 2022

Investigators of an expanded clinical trial have administered an investigational CAR-T cell therapy to the first patient with blood cancer.

Blood Cancer Drug, Copiktra, May Increase Risk of Death, Severe Side Effects, FDA Warns

July 5th 2022

Long-term clinical trial data showed that the use of Copiktra was associated with an increased rate of death and severe side effects for patients with chronic lymphocytic leukemia and small cell leukemia.

Time-Limited Venclexta Regimens Outperform Chemoimmunotherapy in CLL

June 13th 2022

Treatment with Venclexta plus Gazyva, with or without Imbruvica, led to better outcomes than chemoimmunotherapy in patients with chronic lymphocytic leukemia.

Calquence-Based Regimens Continue to Elicit Better Results Than Gazyva Plus Chemotherapy in Untreated Chronic Lymphocytic Leukemia

June 5th 2022

Long-term study results show that outcomes, such as survival and response rates, in patients who have received Calquence-containing treatment regimens continue to outpace outcomes in those who were given Gazyva and chemotherapy.

Better Data Needed to Approve Future PI3K Inhibitors for Blood Cancers, FDA Panel Recommends

April 25th 2022

A panel of experts on the FDA’s Oncologic Drugs Advisory Committee voted that all future approvals of PI3K inhibitors to treat blood cancer be backed by randomized clinical trial data.

Certain Blood Cancer Treatments Pulled from US Market After Treatment Results Fail to Show Improved Survival

April 21st 2022

The pharmaceutical company developing a combination regimen of ublituximab plus Ukoniq (known as U2) pulled the drug duo’s indications for the treatment of multiple types of blood cancer after clinical trial results fell short of improving overall survival.

FDA Places Partial Hold on Trial Investigating Novel Drug in Patients With Leukemia and Lymphoma

April 12th 2022

The FDA’s partial hold means that no new patients with either leukemia or lymphoma can be enrolled onto the trial.

Post-Treatment Venclexta Improves Outcomes and Is Well-Tolerated in CLL

April 12th 2022

Regardless of whether it was guided by minimal residual disease status or given at a fixed dosage, consolidation Venclexta proved to be beneficial in patients with chronic lymphocytic leukemia.

Immunocompromised: Navigating the COVID-19 Pandemic while Living with CLL

March 31st 2022

Learn about the disproportionate impact that the COVID-19 pandemic has on immunocompromised patients with chronic lymphocytic leukemia (CLL), and hear potential solutions from leading CLL experts.

An ‘Equal Playing Field’ Makes up the Available Treatment Options for CLL

February 27th 2022

Regardless of a patient’s age, comorbidity status or disease risk, an expert from Memorial Sloan Kettering Cancer Center notes how targeted therapies have become the standard of care in treating chronic lymphocytic leukemia.

With No CAR-T Cell Therapies Approved for CLL, More Work is Needed to ‘Maximize’ These Treatments

February 14th 2022

More research is necessary, says an expert, to improve responses to CAR-T cell treatments in patients with chronic lymphocytic leukemia.

Calquence Linked to Fewer Heart-Related, Other Toxicities in Patients With CLL Than Imbruvica

January 7th 2022

Treatment with Calquence resulted in fewer toxicities, including atrial fibrillation, flutter and hypertension, in patients with previously treated chronic lymphocytic leukemia, compared with Imbruvica treatment, according to findings from the analysis of a phase 3 trial.

High-Frequency, Low-Dose Calquence-Rituxan Combo May Elicit Safe Responses in Previously Untreated CLL/SLL

December 20th 2021

The combination of Calquence and Rituxan may also be useful during the COVID-19 pandemic as it decreases infusion times and patient interactions, according to an expert.

5 Cancer Clinical Trials You May Have Missed

December 18th 2021

There are many cancer clinical trials that patients can enroll in across the United States. Here is a snapshot of some of the more recent ones.

Calquence Remains Effective and Safe After 3 Years Compared With Standard of Care in Relapsed/Refractory Chronic Lymphocytic Leukemia

December 14th 2021

Calquence, a next-generation BTK inhibitor, significantly prolonged survival compared with standard of care, along with no new side effects at three years in chronic lymphocytic leukemia. These findings also pertained to some patients with high-risk genetic features.

Imbruvica And Rituxan Bests Standard-of-Care Regimen in Patients With Previously Untreated CLL

December 14th 2021

The data demonstrated that the combination of Imbruvica and Rituxan conferred superior progression-free survival results in patients with previously untreated chronic lymphocytic leukemia, compared with the chemotherapies fludarabine and cyclophosphamide plus Rituxan.

Patients With CLL Had Improved Quality of Life on Imbruvica Plus Rituxan

December 13th 2021

Patients with chronic lymphocytic leukemia reported improved quality of life when treated with frontline Imbruvica and Rituxan, followed by continuous treatment with Imbruvica.

Cancer Clinical Trial Enrollment Is Low in the US, and Patient Depression and Anxiety May Play a Role

December 12th 2021

Researchers found that depression and anxiety may skew patient perceptions of participating in blood cancer clinical trials, thus contributing to low enrollment throughout the United States.

Adding Imbruvica to CAR-T Cell Therapy May Improve CLL Outcomes

November 17th 2021

Imbruvica plus Breyanzi, a CAR-T cell therapy, improved outcomes in patients with relapsed/refractory chronic lymphocytic leukemia, according to recent research.

NEXT PAGE
PREVIOUS PAGE